Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy
- 14 July 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , 361-372
Abstract
Background: Therapeutic vaccines represent a potential strategy for HIV-1 control without antiretroviral therapy (ART). We report a first-in-human study on ICVAX™, a PD-1-enhanced HIV-1 therapeutic DNA vaccine. Methods: This NMPA-approved, randomized, double-blind, placebo-controlled, dose-escalation phase I trial (NCT06253533) was conducted at Shenzhen Third People's Hospital, China. Adults with HIV-1 aged 18–50 years on ART were sequentially allocated to 1, 2, or 4 mg dose groups of 15, each randomized 12:3 to ICVAX or placebo. Participants received intramuscular injections with electroporation at Weeks 0, 4, 8, 12, and 36. Primary safety, secondary immunological, and exploratory virological outcomes were recorded. Results: All 45 participants completed the trial, with 12 per ICVAX cohort and 9 in pooled Placebo. Treatment-related adverse events occurred in 100% of placebo and 83.3% of ICVAX recipients, all mild and transient, predominantly local reactions. A ≥2-fold increase of peak ELISpot T-cell responses over baseline was achieved by 75%, 75%, and 58.3% of low-dose, mid-dose, and high-dose recipients, versus 33.3% for Placebo. ICVAX recipients also showed low-frequency Gag-specific T cells expressing CD107a and/or effector cytokines. Conclusions: ICVAX was well-tolerated and elicited robust antigen-specific T-cell responses in ART-suppressed people with HIV-1. Its efficacy will be assessed in future studies.Keywords
Funding Information
- Immuno Cure Group
- Clinical Translational Catalyst programme of Hong Kong Science & Technology Parks Corporation
- Hong Kong Research Grants Council Theme-Based Research Scheme (T11-706/18-N)
- Hong Kong Research Grants Council Theme-Based Research Scheme (T11-702/24-N)
- Shenzhen Science and Technology Innovation Program (JSYJ20240813102007011)
- National Key Research and Development Program of China (2021YFC2301900)
- National Key Research and Development Program of China (2023YFC2308300)
- Shenzhen Clinical Research Centre for Emerging Infectious Diseases (LCYSSQ20220823091203007)
- Shenzhen High-level Hospital Construction Fund
- Immuno Cure Group
This publication has 46 references indexed in Scilit:
- An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19EBioMedicine, 2025
- SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phaseImmunity, 2024
- Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialEBioMedicine, 2024
- Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 VaccinationMolecular Therapy-Oncolytics, 2020
- Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)eClinicalMedicine, 2019
- DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responsesVaccine, 2018
- Human T Cell Development, Localization, and Function throughout LifeImmunity, 2018
- Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trialsVaccine, 2015
- HIV infection: epidemiology, pathogenesis, treatment, and preventionThe Lancet, 2014
- Multiple-site DNA vaccination enhances immune responses in miceVaccine, 2006